Phase 3 Hepatocellular Carcinoma (HCC)
The purpose of the study is to assess the survival of patients treated with Aptocine versus standard of care therapies in the treatment of unresectable hepatocellular carcinoma (HCC), and to demonstrate the safety of Aptocine.
For more information about this trial, please visit the trial registration page at ClinicalTrials.gov: